Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1994-09-19
1997-01-14
Leguyader, John L.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 231, 435 6, 435 911, C07H 2104, C12Q 168, A61K 4800
Patent
active
055941222
ABSTRACT:
The present invention is directed to oligonucleotides comprising nucleotide sequences sufficiently complementary to conserved regions of human immunodeficiency virus genetic material such that when bound to said region, the oligonucleotides effectively prevent expression of the genetic material.
REFERENCES:
patent: 4415732 (1983-11-01), Caruthers et al.
patent: 4458066 (1984-07-01), Caruthers et al.
patent: 4725677 (1988-02-01), K oster et al.
patent: 4959463 (1990-09-01), Froehler et al.
patent: 5110802 (1992-05-01), Cantin et al.
patent: 5166195 (1992-11-01), Ecker
Bennett et al., "Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides" Mol. Pharmacol. (1992) 41:1023-1033.
Sanford, "Applying the PCR principle to AIDS" J. Theor. Biol. (1988) 130:469-480.
Matsukura et al., "A new concept in AIDS treatment: An antisense approach and its current status towards clinical application" Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS, Wickstr om, E., ed., (1991) Wiley-Liss, Inc., New York, pp. 159-178.
Thierry et al., "Liposomal delivery as a new approach to transport antisense oligonucleotides" Gene Regulation: Biology of Antisense RNA and DNA, Erickson et al., eds., (1992) Raven Press, New York, pp. 147-161.
Drug& Market Develop. "Antisense/oligonucleotide therapeutics: Part 2 - Company update" (1993) 4:179-195.
Lelen, "Ag-biotechnology companies move forward on heels of the FDA statement on biofoods" Genet. Eng. News (1992) 12:1, 21-22.
Ratajczak et al., "In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides" Proc. Natl. Acad. Sci. USA (1992) 89:11823-11827.
Sterling, "Systemic antisense treatment reported" Genet. Eng. News (1992) 12:1, 28.
Whitesell et al., "Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: Implications for therapeutic application within the central nervous system" Proc. Natl. Acad. Sci. USA (1993) 90:4665-4669.
Stein et al., "Oligonucleotides as inhibitors of gene expression: A review" Cancer Res. (1988) 48:2659-2668.
Walder, "Antisense DNA and RNA: progress and prospects" Genes & Devel. (1988) 2:502-504.
Marcus-Sekura, "Techniques for using antisense oligodeoxyribonucleotides to study gene expression" Anal. Biochem. (1988) 172:289-295.
Zon, "Synthesis of backbone-modified DNA analogues for biological applications" J. Pro. Chem. (1987) 6:131-145.
Zon, "Oligonucleotide analogues as potential chemotherapeutic agents" Pharm. Res. (1988) 5:539-549.
Van der Krol et al., "Modulation of eukaryotic gene expression by complementary RNA or DNA sequences" Bio Techniques (1988) 6:958-976.
Loose-Mitchell, "Antisense nucleic acids as a potential class of pharmaceutical agents" TIPS (1988) 9:45-47.
Beal et al., "Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation" Science (1992) 251:1360-1363.
Cooney et al., "Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro" Science (1988) 241:456-459.
Knorre et al., "Reactive oligonucleotide derivatives and sequence-specific modification of nucleic acids" Biochimie (1985) 67:785-789.
Iverson et al., "Nonenzymatic sequence-specific cleavage of single-stranded DNA to nucleotide resolution. DNA methyl thioether probes" J. Am. Chem. Soc. (1987) 109:1241-1243.
Meyer et al., "Efficient, specific cross-linking and cleavage of DNA by stable, synthetic complementary oligodeoxynucleotides" J. Am. Chem. Soc. (1989) 111:8517-8519.
Lee et al., "Interaction of psoralen-derivatized oligodeoxyribonucleoside methylphosphonates with single-stranded DNA" Biochem. (1988) 27:3197-3203.
Horne et al., "Recognition of mixed-sequence duplex DNA by alternate-strand triple-helix formation" J. Am. Chem. Soc. (1990) 112:2435-2437.
Webb et al., "Sequence-specific cross-linking of deoxyoligonucleotides via hybridization-triggered alkylation" J. Am. Chem. Soc. (1986) 108:2764-2765.
Webb et al., "Hybridization triggered cross-linking of deoxyoligonucleotides" Nucl. Acids Res. (1986) 14(19):7661-7674.
Shaw et al., "Specific, high-efficiency, triple-helix-mediated cross-linking to duplex DNA" J. Am. Chem. Soc. (1991) 113:7765-7766.
Matteucci et al., "Synthesis and crosslinking properties of a deoxyoligonucleotide containing N.sup.6,N.sup.6 -ethanodeoxyadenosine" Tetrahedron Letters (1987) 28:2469-2472.
Praseuth et al., "Sequence-specific binding and photocrosslinking of .alpha. and .beta. oligodeoxynucleotides to the major groove of DNA via triple-helix formation" Proc. Natl. Acad. Sci. USA (1988) 85:1349-1353.
Vlassov et al., "Sequence-specific chemical modification of double-stranded DNA with alkylating oligodeoxynucleotide derivatives" Gene (1988) 72:313-322.
Fedorova et al., "Complementary addressed modification of double-stranded DNA within a ternary complex" FEBS Letters (1988) 228:273-276.
Capobianco et al., "One pot solution synthesis of cyclic oligodeoxyribonucleotides" Nucl. Acids Res. (1990) 18:2661-2669.
van de Sande et al., "Parallel stranded DNA" Science (1988) 241:551-557.
Froehler et al., "Triple-helix formation and cooperative binding by oligodeoxynucleotides with a 3'-3' internucleotide junction" Biochem. (1992) 31:1603-1609.
Young et al., "Triple helix formation inhibits transcription elongation in vitro" Proc. Natl. Acad. Sci. USA (1991) 88:10023-10026.
Froehler et al., "Oligodeoxynucleotides containing C-5 propyne analogs of 2'-deoxyuridine and 2'-deoxycytidine" Tetrahedron Letters (1992) 33:5307-5310.
Seela et al., "Palindromic octa- and dodecanucleotides containing 2'-deoxytubercidin: synthesis, hairpin formation, and recognition by the endodeoxyribonuclease EcoRI" Biochem. (1987) 26:2232-2238.
Seela et al., "Palindromic oligonucleotides containing 7-deaza-2'deoxyguanosine: solid-phase synthesis of d[(p)GG*AATTCC] octamers and recognition by the endodeoxyribonuclease EcoRI" Nucl. Acids Res. (1986) 14:2319-2332.
Seela et al., "Oligomers eith alternating thymidine and 2'-deoxytubercidin: duplex stabilization by a 7-deazapurine base" Biochem. (1985) 24:7556-7561.
Goodchild et al., PNAS 85, 5507-5511 (1988).
Matthews et al., Analyt. Biochem. 169, 1-25 (1988).
Degols et al., Antiviral Res. 17, 279-287 (1992).
Uhlmann et al. Chem Rev. 90:544-579 (1990).
Johnston et al. Science 260:1286-1293 (1993).
Stein et al. Science 261:1004-1011 (1993).
Rittner et al. NAR 19:1421-1426 (1991).
Milligan et al. Med. Chem. 36:1923-1937 (1993).
Shibahara et al. NAR 17:239-252 (1989).
Weis Science News, 108-109, vol. 139, 1991.
Yu et al. J. Neurosci. Res. 30:72-79 (1991). Provided as BIORIS Acc No. 92138937.
Matner et al. Nature 313:277 (1985).
Kole et al. Adv. Drug Deliver. Rev. 6:271 (1991).
McGraw et al. Bio Techniquce 8:674 (1990).
Genesys Pharma Inc.
LeGuyader John L.
LandOfFree
Antisense oligonucleotides targeted against human immunodeficien does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotides targeted against human immunodeficien, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides targeted against human immunodeficien will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1389278